Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2022 | 03-2022 | 12-2021 | 09-2021 | 06-2021 | |
| Sales | 89,343 | 79,935 | 83,389 | 81,647 | 86,975 |
| Cost of Goods | 8,270 | 6,100 | 3,509 | 4,175 | 3,136 |
| Gross Profit | 81,073 | 73,835 | 79,880 | 77,472 | 83,839 |
| Operating Expenses | 222,936 | 210,567 | 182,953 | 167,475 | 166,751 |
| Operating Income | -141,593 | -136,632 | -102,564 | -89,828 | -82,776 |
| Interest Expense | 6,052 | 6,584 | 3,804 | 8,683 | 8,517 |
| Other Income | -10,215 | -8,546 | -16,070 | 25,695 | -30,672 |
| Pre-tax Income | -157,860 | -151,762 | -122,438 | -72,816 | -121,965 |
| Income Tax | 302 | 558 | 20 | 182 | 463 |
| Net Income Continuous | -158,162 | -152,320 | -122,458 | -72,998 | -122,428 |
| Net Income | $-158,162 | $-152,320 | $-122,458 | $-72,998 | $-122,428 |
| EPS Basic Total Ops | -2.26 | -2.19 | -1.78 | -1.08 | -1.81 |
| EPS Basic Continuous Ops | -2.26 | -2.19 | -1.78 | -1.08 | -1.81 |
| EPS Diluted Total Ops | -2.26 | -2.19 | -1.78 | -1.08 | -1.81 |
| EPS Diluted Continuous Ops | -2.26 | -2.19 | -1.78 | -1.08 | -1.81 |
| EBITDA(a) | $-135,626 | $-130,650 | $-96,923 | $-84,623 | $-78,084 |